
PetMed Express (PETS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2024Income Metrics
Revenue
53.0M
Gross Profit
14.9M
28.14%
Operating Income
-450.0K
-0.85%
Net Income
-707.0K
-1.33%
EPS (Diluted)
$-0.03
Balance Sheet Metrics
Total Assets
144.8M
Total Liabilities
48.6M
Shareholders Equity
96.2M
Debt to Equity
0.51
Cash Flow Metrics
Operating Cash Flow
-4.2M
Free Cash Flow
-1.9M
Revenue & Profitability Trend
PetMed Express Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 281.1M | 256.6M | 272.3M | 303.6M | 284.1M |
Cost of Goods Sold | 202.4M | 185.8M | 195.3M | 219.3M | 202.9M |
Gross Profit | 78.6M | 70.7M | 76.9M | 84.3M | 81.2M |
Gross Margin % | 28.0% | 27.6% | 28.3% | 27.8% | 28.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 79.8M | 61.1M | 49.9M | 51.4M | 48.0M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 79.8M | 61.1M | 49.9M | 51.4M | 48.0M |
Operating Income | -8.2M | 6.1M | 24.3M | 30.5M | 31.0M |
Operating Margin % | -2.9% | 2.4% | 8.9% | 10.1% | 10.9% |
Non-Operating Items | |||||
Interest Income | - | 2.1M | 335.0K | 314.0K | 1.7M |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 1.4M | 944.0K | 1.0M | 1.3M | 1.2M |
Pre-tax Income | -6.3M | 7.4M | 24.2M | 31.0M | 33.9M |
Income Tax | 1.2M | 2.3M | 5.5M | 7.0M | 8.0M |
Effective Tax Rate % | 0.0% | 31.0% | 22.6% | 22.7% | 23.7% |
Net Income | -7.5M | 5.1M | 18.7M | 23.9M | 25.9M |
Net Margin % | -2.7% | 2.0% | 6.9% | 7.9% | 9.1% |
Key Metrics | |||||
EBITDA | -1.1M | 9.6M | 27.0M | 33.0M | 33.2M |
EPS (Basic) | $-0.37 | $0.25 | $1.05 | $1.53 | $1.29 |
EPS (Diluted) | $-0.37 | $0.25 | $1.04 | $1.52 | $1.29 |
Basic Shares Outstanding | 20395959 | 20274786 | 20176000 | 20060000 | 20041000 |
Diluted Shares Outstanding | 20395959 | 20274786 | 20176000 | 20060000 | 20041000 |
Income Statement Trend
PetMed Express Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 55.3M | 104.1M | 111.1M | 118.7M | 103.8M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 3.3M | 1.7M | 1.9M | 2.6M | 3.8M |
Inventory | 28.6M | 19.0M | 32.5M | 34.4M | 17.9M |
Other Current Assets | 6.3M | 4.7M | 4.9M | 4.5M | 3.5M |
Total Current Assets | 93.6M | 130.4M | 151.0M | 161.2M | 129.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.4M | 0 | 0 | 0 | 0 |
Goodwill | 64.5M | 860.0K | 860.0K | 860.0K | 860.0K |
Intangible Assets | 11.2M | 860.0K | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 5.0M | 5.0M | 3.4M | - | - |
Total Non-Current Assets | 76.2M | 37.0M | 28.7M | 26.3M | 26.3M |
Total Assets | 169.9M | 167.5M | 179.7M | 187.5M | 155.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 37.0M | 25.2M | 27.5M | 39.5M | 19.7M |
Short-term Debt | 459.0K | - | - | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 72.2M | 57.5M | 56.2M | 44.9M | 24.3M |
Non-Current Liabilities | |||||
Long-term Debt | 995.0K | 0 | - | - | - |
Deferred Tax Liabilities | - | 0 | 936.0K | 1.3M | 970.0K |
Other Non-Current Liabilities | - | 3.8M | - | - | - |
Total Non-Current Liabilities | 995.0K | 0 | 0 | 1.3M | 970.0K |
Total Liabilities | 73.2M | 57.5M | 56.2M | 46.2M | 25.3M |
Equity | |||||
Common Stock | 21.0K | 21.0K | 21.0K | 20.0K | 20.0K |
Retained Earnings | 71.6M | 91.7M | 111.8M | 134.1M | 126.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 96.7M | 110.0M | 123.4M | 141.3M | 130.0M |
Key Metrics | |||||
Total Debt | 1.5M | 0 | 0 | 0 | 0 |
Working Capital | 21.5M | 72.9M | 94.7M | 116.3M | 104.7M |
Balance Sheet Composition
PetMed Express Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -7.5M | 5.1M | 18.7M | 23.9M | 25.9M |
Depreciation & Amortization | 7.1M | 3.5M | 2.7M | 2.4M | 2.3M |
Stock-Based Compensation | 6.9M | 6.6M | 4.5M | 3.3M | 2.8M |
Working Capital Changes | -2.4M | 11.1M | -9.6M | 4.5M | 5.4M |
Operating Cash Flow | 4.3M | 24.8M | 15.6M | 32.9M | 36.2M |
Investing Activities | |||||
Capital Expenditures | -4.5M | -5.3M | -1.8M | -2.4M | -2.3M |
Acquisitions | -36.2M | -5.0M | 0 | 0 | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -40.7M | -10.3M | -1.8M | -2.4M | -2.3M |
Financing Activities | |||||
Share Repurchases | - | - | 0 | 0 | -11.5M |
Dividends Paid | -12.4M | -24.5M | -24.4M | -22.7M | -21.8M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -12.4M | -24.5M | -24.4M | -22.7M | -33.3M |
Free Cash Flow | -194.0K | 22.5M | 16.7M | 37.6M | 36.5M |
Net Change in Cash | -48.8M | -10.0M | -10.6M | 7.7M | 545.0K |
Cash Flow Trend
PetMed Express Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
303.00
Forward P/E
-101.00
Price to Book
0.65
Price to Sales
0.25
PEG Ratio
-4.33
Profitability Ratios
Profit Margin
0.15%
Operating Margin
-0.85%
Return on Equity
0.36%
Return on Assets
0.93%
Financial Health
Current Ratio
1.43
Debt to Equity
1.15
Beta
0.82
Per Share Data
EPS (TTM)
$0.01
Book Value per Share
$4.66
Revenue per Share
$12.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
pets | 62.6M | 303.00 | 0.65 | 0.36% | 0.15% | 1.15 |
Walgreens Boots | 10.5B | 27.10 | 1.46 | -69.58% | -4.07% | 409.88 |
High Tide | 248.5M | -61.20 | 1.77 | -6.69% | -1.76% | 44.69 |
Wellgistics Health | 56.8M | -5.47 | 10.27 | -2,124.65% | -135.22% | 571.67 |
Scienture Holdings | 19.5M | 2.37 | 0.25 | -54.26% | 4.39% | 5.30 |
Hong Kong Pharma | 11.5M | 6.26 | 2.31 | -0.59% | -0.13% | 47.60 |
Financial data is updated regularly. All figures are in the company's reporting currency.